Tag: Fate Therapeutics
-
Here’s Why Fate Therapeutics Could Run Back to $95
Keep an eye on Fate Therapeutics (FATE). Oversold, the stock is seeing good momentum after highlighting positive interim Phase 1 data from the Company’s FT516 program for patients with relapsed / refractory B-cell lymphoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. “These additional data from our Phase 1 study of FT516…
-
This is Why Fate Therapeutics is Up $30 Today
Fate Therapeutics (FATE) has become one of the hottest biotech stocks of the year. Since 2020, the stock ran from a low of $18.80 to a recent high of $80.19, good for a return of 327%, as compared to the iShares NASDAQ Biotech ETF (IBB), which is up 25%. On Monday morning, the stock was…